There is a guava tree right in front of my apartment building. The nice thing about this is that, thanks to its strong fragrance, I get a fun, tropical…
The time has come, people, and I’m getting ready. I’ve had a rough week of workouts, but I’m not going to let it shake me. I’ve trained for tomorrow’s…
Who would have ever thought that cauliflower would be good on the grill? I certainly didn’t, but it is fantastic! When I last made this, I omitted the asparagus because it was out of season.
Following an ongoing FDA review of the diabetes drug Avandia (rosiglitazone) the FDA will require that GlaxoSmithKline (GSK) develop a restricted access program for Avandia under a risk evaluation and mitigation strategy, or REMS. Under the REMS, Avandia will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone), the only other drug in this class...
John Lachin had one last monkey wrench to throw in. He agreed that the problem was not severe hypoglycemia, and was not rapid lowering of HbA1c...
This week at the 46 th Annual Meeting of the European Association for the Study of Diabetes (EASD) Boehringer Ingelheim presented data from its linagliptin phase III clinical trial. Linagliptin belongs to the novel class of DPP-4 inhibitors and is currently...
I often feel like living with diabetes is an extreme sport. It may not involve much physical exertion, but the mental effort required — counting…
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients...
Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes. The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD)...
Biodel Inc. researchers presented results of a clinical study evaluating a new pH-neutral formulation of Linjeta(TM) (VIAject(R)) at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm today. Dr. Tim Heise (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues reported that...